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Abstract
Background: Patients with cartilage-hair hypoplasia (CHH), a rare metaphyseal chondrodysplasia, manifest severe
growth failure, variable immunodeficiency and increased risk of malignancies. The impact of CHH on gynecologic
and reproductive health is unknown. Vulnerability to genital infections may predispose CHH patients to prolonged
human papillomavirus (HPV) infections potentially leading to cervical, vaginal and vulvar cancer.
Methods: We carried out gynecologic evaluation, pelvic ultrasound and laboratory assessment in 19 women with
genetically confirmed CHH. All patients were clinically examined and retrospective data were collected from
hospital records.
Results: The women ranged in age from 19.2 to 70.8 years (median 40.8 years) and in height from 103 to 150 cm
(median 123 cm). All women had undergone normal pubertal development as assessed by breast development according
to Tanner scale and by age of menarche (mean 12.5 yrs., range 11–14 yrs). Despite significant short stature and potentially
small pelvic diameters, a well-developed uterus with fairly normal size and shape was found by pelvic ultrasound in
most of the patients. Ovarian follicle reserve, assessed by ultrasound was normal in relation to age in all premenopausal
women it could be assessed (12 cases). Anti-Müllerian hormone was normal in relation to age in 17 women (89%). HPV
was detected in 44% (8/18) and three women carried more than one HPV serotype; findings did not associate with
immunological parameters. Three patients had a concurrent cell atypia in Pap smear.
Conclusions: Pubertal development, reproductive hormones and ovarian structure and function were usually normal in
women with CHH suggesting fairly normal reproductive health. However, the immunodeficiency characteristic to CHH may
predispose the patients to HPV infections. High prevalence of HPV infections detected in this series highlights the
importance of careful gynecologic follow up of these patients.
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Background
Cartilage-hair hypoplasia (CHH; MIM #250250) is a rare
autosomal recessive metaphyseal chondrodysplasia with
an incidence of 1: 23000 births in Finland [1, 2]. It is
characterized by severe short-limbed growth failure
(mean adult height for males 131 cm and for females
123 cm), thin and sparse hair, and variable immunodefi-
ciency. The risk of malignancies is sevenfold increased,
non-Hodgkin lymphoma being the most common
malignancy with a 90-fold incidence compared with nor-
mal population [3]. CHH is caused by biallelic mutations
in the noncoding RNA gene, RMRP. RMRP mutations
disrupt ribosomal processing and cell cycle, leading to
defective cell proliferation [4]. CHH is highly variable in
severity with phenotypic differences also within families.
While major clinical manifestations of CHH are
well-described, almost no data are available on its po-
tential effect on gynecologic and reproductive health and
vulnerability to genital infections and HPV-related
cancers [2, 5–7]. All these previous studies were based
on questionnaires or case reports. None of the previous* Correspondence: elina.holopainen@hus.fi1Women’s Hospital, HUS Helsinki University Hospital and University of
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clinical series included gynecologic examination or
laboratory evaluation.
Whether fertility is affected in CHH also remains unclear.
In a cohort of 11 adult CHH males, serum concentrations
of testosterone, inhibin B and gonadotropins were mainly
normal. However, semen analyses showed impaired sper-
matogenesis [8]. Recent case reports have described two
CHH women with hypogonadism [7] and pregnancy
outcome of one woman with CHH [6]. There are no other
studies evaluating reproduction in patients with CHH.
This lack of data prompted us to carry out a cross-
sectional study on gynecologic health in a relatively
large cohort of adult women with CHH. We evalu-
ated all subjects clinically and by performing hormo-
nal laboratory measurements and pelvic ultrasound.




The study protocol was approved by the Institutional Re-
view Board of the Children’s Hospital, University of
Helsinki and all study participants gave a written
informed consent. Patients were identified from the
Finnish Skeletal Dysplasia Register which includes > 160
patients with genetically confirmed CHH. All RMRP mu-
tations had been detected by Sanger sequencing either at
Laboratory HUSLAB, Finland, or as a part of previous or
ongoing research at Folkhälsan Institute of Genetics,
Helsinki [4, 9]. All 55 women aged over 18 years were in-
vited to the study; 19 CHH females agreed, accounting for
a participation rate of 34.5% (Fig.1).
Methods
Hospital records were reviewed for relevant data. Patients
were interviewed for a detailed medical history. Complete
gynecologic and pelvic ultrasound examinations (GE
Healthcare Voluson S6) were performed by an experienced
gynecologist (EH). Pubertal status was recorded according
to Tanner’s classification [10]. Antral follicle count (AFC) of
the ovaries was considered normal if it was between 10th
and 90th percentiles of age-specific normal values [11].
Pap smear and cervical HPV test were obtained when
anatomically possible. Cervical samples for HPV test
were taken by APTIMA cervical collection and transport
KIT and HPV subtypes were analyzed by PCR and
Luminex suspension array technology [12]. The test de-
tects 15 high-risk HPV types, six potentially high-risk
types and 19 low-risk HPV types.
Blood cell count and serum concentrations of sex
hormones, prolactin, thyroid stimulating hormone, go-
nadotropins and Anti-Müllerian hormone (AMH) were
measured during clinical visit. Serum estradiol was ex-
tracted from serum with diethyl ether and quantitated
by LC-MS/MS (liquid chromatography-tandem mass
spectrometry) using a TQ5500 mass spectrometer (AB
Sciex, Concord, Canada). The between-run coefficient of
variations (CV %) were 4.4–5.1% for serum samples at
concentrations 330–900 pmol/L.
Serum luteinizing hormone (LH) and follicle-stimulating
hormone (FSH) concentrations were measured using an
electrochemiluminescence immunoassay (Abbott Diagnos-
tics, USA). Anti-Müllerian hormone (AMH) was quanti-
tated with an ELISA assay (AMH Gen II ELISA, Beckman
Coulter, Brea, CA, USA). Limit of detection (LoD) was
0.08 μg/L and limit of quantitation (LoQ) 0.16 μg/L.
Intra-assay and inter-assay CV% was < 6% in the range
3.8–16.5 μg/L. Total CV % was < 8%. Age-specific
limits of AMH were applied [13]. The method of AMH
measuring was changed in the laboratory during the study.
In four patients, Anti-Müllerian hormone (AMH) was
Fig. 1 Flow chart showing the proportions and ages of patients
who consented and did not consent to the study
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quantitated with an electrochemiluminometric assay on a
cobase 411 automatic immunoanalyzer (Elecsys AMH
Plus, Roche Diagnostics, Mannheim, Germany). Limit of
detection (LoD) was 0.01 μg/L and limit of quantitation
(LoQ) 0.03 μg/L. Intra-assay CV % was < 2% and
inter-assay CV % was < 5% in the range 0.2–19 μg/L of
AMH. AMH results with this method are 30% lower than
in the ELISA method previously used. For obtaining
comparable values by the two different methods, we used
mathematical conversion for values detected by Elecsys
AMH Plus in four patients (1,3x detected value). For
plasma levels of immunoglobulins and lymphocyte counts
local laboratory reference values were applied as described
previously [14].
Statistical analysis
Standard statistical methods were used as appropriate.
Median, mean and/or standard deviation estimates were
computed for variables such as age, length and weight.
Fisher’s exact test and logistic regression analysis were




The cohort characteristics are described in Table 1 and
clinical and laboratory manifestations of immunodeficiency
are shown in Table 2. The median age of the 19 study par-
ticipants was 41.8 years (range 19.2–70.8 yrs). All had
undergone a normal spontaneous puberty; the median age
at menarche was 12.5 years, varying from 11 to 14 years.
Five women were regarded postmenopausal, defined by ei-
ther i) duration of amenorrhea of more than 12 months
and FSH > 30 IU/L (three women) or ii) history of meno-
pausal symptoms and current use of hormonal replacement
therapy (two women). Median adult height was 123 cm
(103–150 cm) and median weight 41.8 kg (29.0–80.0 kg).
Fifteen patients were homozygous for the RMRP founder
mutation c.70A >G and four patients were compound
heterozygous for c.70A >G and c.262G >T mutations.
Gynecologic status
All patients had normal breast development, either
Tanner stage M4 (n = 1) or M5 (n = 18). Pubic hair was
fully developed (Tanner stage P5, n = 6) or almost fully
developed (P4, n = 7) in 68% and partly developed (P3,
n = 2) or totally absent (P1, n = 3) in 32%. Those with P1
had total alopecia.
Pelvic ultrasound examination was performed vagi-
nally in 18 women and abdominally in one woman. In
16 women, the structure of the uterus was considered
normal with regard to age, stage of menstrual cycle and
the patient’s current hormonal therapy (Table 1). Two
postmenopausal patients had small, asymptomatic













Menarche (median, yrs) 12.5










Current hormonal therapy 5/19
Combined contraception pills 1
Progestin only -pills 2









Repeated genital infections 6/19
Previous malignancyb 3
Leucocytes (× 109/L) (range, median) 3.2–13.4; 5.6
Lymphocytes (× 109/L) (range, median) 0.5–2.58; 1.22
Neutrophiles (× 109/L) (range, median) 1.74–10.65; 3.37
aYes = one or several episodes of otitis media and/or rhinosinuitits;
Intermediate = pneumonia necessitating hospitalization and/or recurrent otitis
media and/or rhinosinuitis requiring surgical treatment
b1 squamous cell carcinoma,2 basal cell carcinomas
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leiomyomas and one postmenopausal woman had thick-
ened endometrium (4.8–6.3 mm) during continuous
hormone replacement therapy.
Median uterine width, determined as the maximum
anterior-posterior distance measured in the mid portion
of uterine body on a sagittal view, was 27 mm (range
20–38 mm) and median length of uterine corpus, mea-
sured from the fundus to the internal orifice of the
uterus on a sagittal view, was 38 mm (range 26–70 mm).
The 41-year old woman with the smallest, pre-pubertal--
size uterus (anterior-posterior measurement 20 mm, cor-
pus length 26 mm) had undergone spontaneous
menarche at the age of 11 years, used currently
progestin-only pills and had sparse menstrual flow. She
had never tried to become pregnant. Another pre-meno-
pausal 46-year old woman also had a relatively small
uterus, with corpus anterior-posterior measurement of
20 mm and corpus length of 29 mm. However, she had
used levonorgestrel-releasing intrauterine device for
years suggesting fairly normal uterine cavity. In all other
pre-menopausal women corpus anterior-posterior meas-
urement was > 25 mm and corpus length > 30 mm.
The structure of ovaries could be assessed in 16/19
subjects and all were considered normal in relation
to age, phase of menstrual cycle and use of hormo-
nal therapy. In three postmenopausal women (aged
60–70 years) ovaries could not be identified.
AFC in both ovaries could be assessed in 12 premeno-
pausal women and was normal in all. In two cases, AFC
from only one ovary could be reliably counted (Table 3).
Laboratory parameters
Blood cell count was analyzed in 18/19 cases. Mean
hemoglobin was 131 g/L (range 111–146 g/L). Only one
woman had hemoglobin under normal range (111 g/L,
normal values 117–155 g/l). Mean white blood cell
count was 6.3 x e9/L (range 3.2–13.4 x e9/L) and platelet
count 275 x e9/L (range 147–398 x e9/L).
AMH was measured from all 19 patients and was
under detection limit in all postmenopausal women
(n = 5) and in the two perimenopausal women (aged >
45 yrs). Most of the premenopausal women had normal
AMH according to age-specific reference values (Table 3).
Two women had lower than expected AMH levels and
Table 2 Clinical and laboratory manifestations of immunodeficiency in 19 patients with cartilage-hair hypoplasia







2 + NA NA NA NA NA
3 + None Normal Low TLC, CD3+, CD4+, CD8+, CD19+ NA NA
11 + OM, Sin Normal Low CD19+ Abnormal NA
12 + Sin Normal Normal Abnormal no
13 + Sin NA NA Normal NA
15 + BE, Pn, Sin requiring surgery Low IgG Low CD3+, CD4+, CD19+ NA NA
16 + BE, Pn, Sin Normal Low CD3+, CD4+, CD8+ Abnormal yes
17 + None Normal Low TLC, CD8+ NA NA
1 – OM, Pn Normal Low TLC, CD3+, CD4+, CD8+, CD16/56+ NA NA
4 – OM, severe varicella requiring
hospitalization
Normal Low TLC, CD3+, CD4+, CD8+, CD19+ NA yes
5 – OM, Sin Normal Low TLC, CD3+, CD4+, CD8+ Abnormal NA
6 – None Normal Low CD3+, CD4+, CD8+, CD19+ Abnormal NA
8 – OM Normal Normal Normal yes
9 – Sin requiring surgery Normal Low CD19+ NA NA
10 – OM, Sin requiring surgery Ig substitution Low CD3+, CD4+, CD8+, CD19+ Abnormal yes
14 – BE, OM, Sin requiring surgery Normal Normal Abnormal yes
18 – BE, Pn, Sin requiring surgery Low IgM Low CD19+ NA no
19 – None Normal Normal NA NA
7 NA Boils, OM, autoimmunity Ig substitution Low TLC, CD3+, CD4+, CD8+, CD19+ NA yes
BE bronchiectasis, HPV human papillomavirus cervical carriage, Ig immunoglobulin, NA data not available, OM recurrent otitis media, Pn recurrent pneumonia, Pt
patient number, SAD specific antibody deficiency, Sin recurrent rhinosinusitis, TLC total lymphocyte count
aLocal laboratory reference values were applied, measured as described previously in (14)
bLocal laboratory reference values were applied, measured by flow cytometry as described previously in (14)
cData were obtained from hospital records, measurement performed by various methods
dSAD was defined as inadequate antibody response to Pneumovax®: a fourfold rise in antibody titers and post-immunization antibody levels ≥0.35 μg/ml to < 70%
of serotypes, measured as described previously in (14)
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there was a discrepancy between the age-specific AMH
level and AFC detected by vaginal ultrasound. The first
one (patient #2, Table 3) was a young woman with normal
AFC (12) while AMH of 0.94 μg/L suggested lower
ovarian reserve. The other patient (patient # 9, Table 3)
had normal AFC (10), but AMH was under detection level
(< 0.2 μg/L). Both had regular cycles (period 28) and did
not use hormonal therapy. One patient had low-normal
level of AMH with normal AFC (patient # 7, Table 3). In
none of the patients both AFC and AMH suggested lower
than normal age-specific ovarian reserve.
FSH, LH and estradiol levels were consistent with the
phase of cycle or use of hormone treatment (Table 3).
Thyroid stimulating hormone and testosterone levels
were all in normal range.
Prolactin level was increased in two women (2460 mU/L
and 588 mU/L; normal range 50–500 mU/L), both women
were on psychiatric medication affecting prolactin secretion.
Pap smear and HPV-tests
Pap smear and cervical HPV test were obtained from
18/19 cases. Altogether 9 women had abnormal findings;
these are presented in Table 4. Eight of the 18 women
(44%) had a positive HPV test. Five were positive for one
subtype, three of which were of high-risk types. Another
two women had two high-risk subtypes. Finally, one
woman tested positive for three different HPV subtypes,
one of which was classified as a high-risk type. We
found no correlation between the HPV status and any
other clinical manifestations of immunodeficiency or
Table 3 Antral follicle count and hormone levels in 14 premenopausal women with cartilage-hair hypoplasia
Study subject Age group Current hormonal treatment Day of menstrual cycle AFC (N) FSH (IU/L) LH (IU/L) E2 (nmol/L) AMH (ug/L)
1 19–30 CC – 18 3.7 2.3 0.179 1.97
2 19–30 9 12 5 3.8 0.643 0.94
3 19–30 14 15 14 25.2 0.434 2.29
4 19–30 26 18 5.7 7.2 0.316 4.66
5 19–30 PP – 7a 7.3 4.9 0.07 3.68
6 19–30 14 10 2 0.9 0.264 1.87
7 19–30 20 16 1.8 0.6 0.49 1.39
8 31–40 5 14 5.6 4.9 0.32 5.68
9 31–40 17 10 6 12.5 0.579 < 0.2
10 31–40 19 3a 2.7 1.6 0.423 0.63
11 41–50 PP – 4 5 1.6 0.081 0.22
12 41–50 20 9 3.1 3.8 0.336 1.34
13 41–50 t.a., am 5 8.5 4.8 0.231 < 0.2
14 41–50 4 mo am 1 68.4 40.9 0.046 < 0.2
AFC antral follicle count, AMH anti-Müllerian hormone, CC combined contraception, E2 estradiol, FSH follicle-stimulating hormone, LH luteinizing hormone, mo
months, N number, PP progestin-only pill, am amenorrhea; t.a. endometrium thermoablation done; aDetected from one ovary only. Numbers in bold represent
values below normal age-specific values and numbers in italics low normal age-specific values. AMH values detected by two different methods are converted
mathematically to correspond each other as described in detail in Methods. Ages are given as age groups to ensure anonymity
Table 4 Abnormal Pap smear and human papilloma virus test results in nine women with cartilage-hair hypoplasia. Ages are given
as age groups to ensure anonymity
Study subject Age group Previous abnormal Pap smear Current Pap smear Positive HPV test HPV types High-risk HPV type
1 19–30 NA ASC-US – – –
2 19–30 NA ASC-US + 42 No
3 19–30 Yes LSIL + 56,(66,67) Yes
11 41–50 Yes Normal + 16 Yes
12 41–50 Yes ASC-US + 52,59 Yes
13 41–50 No Normal + 56 Yes
15 > 60 No Normal + 30 No
16 > 60 No Normal + 74 No
17 > 60 No Normal + 16,18 Yes
ASC-US atypical squamous cells of undetermined significance, HPV human papilloma virus, yrs years, LSIL low-grade squamous intraepithelial lesions, NA data
not available
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previously measured blood lymphocyte subset counts or
serum immunoglobulin levels (Table 2). All patients with
high-risk HPV had recently undergone thorough im-
munologic evaluation with normal counts of T and B
cells and normal immunoglobulin A, M and G levels.
Discussion
Little is known about gynecologic health in women with
CHH and our study provides important novel data that
can be implemented in the management and follow-up
of patients with CHH and increase our knowledge on
gynecological issues more widely among women with
skeletal dysplasia. The main findings of our study in-
clude normal pubertal development, mostly normal
genital anatomy and a high prevalence of HPV positivity.
We have previously described two young CHH women
with absent spontaneous pubertal development and
reduced ovarian reserve [7]. However, in this study con-
sisting of 19 women with CHH and severe disproportional
growth failure, pubertal development and sexual matur-
ation were normal as assessed by Tanner scale and age of
menarche. Further, the size of uterus was within normal
range in 18/19 women. In one woman, at age 41 years, the
size of uterus resembled pre-pubertal uterus [15, 16].
However, she had a spontaneous menarche and history of
regular cycles suggesting fairly normal estrogen produc-
tion. It remains unknown whether the small uterus is due
to direct effects of aberrant RMRP function or mediated
by e.g. endocrine factors. AFC was normal in relation to
age in all those who could be evaluated, suggesting fairly
normal fertility potential in this patient group. The lack of
pubarche in three patients is likely to be a result from im-
paired germ-cell proliferation in the hair follicles.
For practical reasons blood tests for hormonal mea-
surements were taken during clinical appointment.
Three women were on hormonal contraception at that
time. Combined contraception may decrease the level of
AMH and number of AFC resulting in underestimation
of fertility potential [17, 18]. However, in a woman using
combined contraception in our series, AMH and AFC
were normal. In two other patients, progestin only pills
were used. Their effect on hormonal levels is less evident
than that of combined contraception [17].
Sexually active CHH women are at risk for acquiring
HPV and combined immunodeficiency may predispose
them to prolonged or severe infection. A Finnish series
of women attending HPV screening during 2003–2005
showed age –specific HPV positivity to vary from 2.8–
24.2% in women aged 25–65 years [19]. In our series
one or more HPV subtypes were found in 44% (8/18)
patients with CHH. Two of our patients with HPV were
under 25 years of age, and the prevalence in this
age-group is known to be higher [20]. However, sponta-
neous recovery of HPV infection is more common in the
young age group. Five of those with HPV (62.5%, 5/8) had
high-risk HPV subtypes. In the Finnish population,
high-risk subtypes have been found in 41.2–65.3% of HPV
positive screening samples [19]. Since prolonged infections
with high-risk HPV subtypes predispose to cervical cancer,
careful and systematic follow-up of abnormal Pap smears
is of utmost importance in immune deficient CHH
patients. Also, HPV vaccination should be considered.
In our patients with high-risk HPV carriage, normal
lymphocyte subsets and immunoglobulin levels have
been documented previously, highlighting the import-
ance of screening also CHH patients with subclinical
immunodeficiency.
Most of the CHH women in our series were or had
been sexually active, indicating a need for reliable and
suitable contraception. In a previous study, intrauterine
device (IUD) was used only by 8% of short-statured
women [5]. This may be explained by fear of potential
difficulties or complications in IUD insertion caused by
disproportionate pelvic diameters and the fact that Cop-
per IUD can exacerbate menstrual cramps and men-
strual flow. However, nowadays, levonorgestrel releasing
IUD is an effective contraceptive method treating also
heavy menstruation. Based on the possibility of perform-
ing clinical gynecologic examination and the normal
uterine measurements found in the present study, we re-
gard the use of levonorgestrel releasing IUD a valuable
option for women with CHH. By reducing menstrual
flow, it may also have a positive effect on potential
anemia due to bone marrow failure, a possible complica-
tion in CHH.
Our study is limited due to the relatively small size
of the cohort and the low participation rate which
may cause bias. However, in rare diseases larger co-
horts are often impossible to obtain. In CHH, severe
short stature further complicates participation of indi-
viduals living far from the study center. The partici-
pation rate was comparable to our previous studies
on CHH. Further, our study permit did not allow us
to collect data on the offspring’s health, including
postnatal growth. Despite these limitations our study
is the largest gynecological evaluation ever performed
in CHH or any other skeletal dysplasia and thus pro-
vides valuable new data. Further studies are needed to
further elucidate the largely unknown field of
gynecological health in women with skeletal dysplasia
and the outcomes of their pregnancies.
Conclusions
Immunodeficiency and increased risk for malignancies
contribute to significant morbidity in CHH patients.
While major clinical manifestations of CHH are
well-described, only little is known about gynecologic
health in CHH. In this prospective series reproductive
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hormones and health were fairly normal. However, high
prevalence of HPV infections detected in this series
highlights the importance of careful gynecologic follow
up of these patients since immunodeficiency may predis-
pose CHH patients to HPV infections.
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